Skip to main content
SpringerLink
Log in

Aldose Reductase Inhibitors in the Treatment of Diabetic Neuropathy

A Review of the Rationale and Clinical Evidence

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

This review considers the definition of clinical diabetic neuropathy and the theoretical basis for the use of aldose reductase inhibitors in the treatment of distal sensorimotor neuropathy, the most common clinical problem. Myoinositol depletion is related to hyperglycaemia-induced polyol activity, changes which are associated with early functional deficits in acute experimental diabetes. These changes are reversible by the administration of aldose reductase inhibitors, and this provides the rationale for the treatment of human diabetic neuropathy with these agents. Many early trials of these drugs have produced some evidence of clinical benefit in patients with diabetic neuropathy, but interpretation of data is difficult as patient selection and neuropathy definition are not yet standardised. In addition, it is possible that once the neuropathic process is initiated, there is a point where it becomes irreversible, and treatment with aldose reductase inhibitors may therefore be of more relevance in early neuropathy. Long term double-blind multicentre trials are in progress, and preliminary data from some of these are reasonably encouraging. In conclusion, the results from clinical trials of the aldose reductase inhibitors in this difficult area are sufficiently encouraging to lead us to be optimistic about their future development, and continuing work should clarify their potential role with respect to the prophylaxis and treatment of diabetic neuropathy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Archer AG, Watkins PJ, Thomas PK, Sharma AK, Payan J. The natural history of acute painful neuropathy in diabetes mellitus. Journal of Neurology, Neurosurgery and Psychiatry 46: 491–499, 1983

    Article  CAS  Google Scholar 

  • Bloom S, Till S, Sonksen P, Smith S. Use of a biothesiometer to measure individual vibration thresholds and their variation in 519 non-diabetic subjects. British Medical Journal 288: 1793–1795, 1984

    Article  PubMed  CAS  Google Scholar 

  • Boulton AJM, Atiea J, DeLeeuw IH, et al. The efficacy and safety of the aldose reductase inhibitor tolrestat in the treatment of chronic sensori motor diabetic neuropathy. Abstract. Diabetologia 32: 469A, 1989

    Google Scholar 

  • Boulton AJM, Knight G, Drury J, Ward JD. The prevalence of symptomatic, diabetic neuropathy in an insulin-treated population. Diabetes Care 8: 125–128, 1985

    Article  PubMed  CAS  Google Scholar 

  • Boulton AJM, the Tolrestat in Neuropathy Study Group. Effect of tolrestat, a new aldose reductase inhibitor, on nerve conduction and parasthetic symptoms in diabetic neuropathy. Abstract no. 61. Diabetologia 29: 521A, 1986

    Google Scholar 

  • Boulton AJM, Ward JD. Diabetic neuropathies and pain. Clinics in Endocrinology and Metabolism 15(4): 917–931, 1986

    Article  PubMed  CAS  Google Scholar 

  • Brownlee M, Cerami A, Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. New England Journal of Medicine 318: 1315–1321, 1988

    Article  PubMed  CAS  Google Scholar 

  • Bruyn GW, Garland H. Neuropathies of endocrine origin. In Vinken PJ & Bruyn GW (Eds) Handbook of clinical neurology, Vol. 8, pp. 29–71, North Holland Publishing Company, Amsterdam, 1970

    Google Scholar 

  • Christiensen JE, Varnek L, Gregersen G. The effect of an aldose reductase inhibitor (sorbinil) on diabetic neuropathy and neural function of the retina: a double-blind study. Acta Neurologica Scandinavica 71: 164–167, 1985

    Article  Google Scholar 

  • Clements RS, Bell DSH. Diagnostic, pathogenic and therapeutic aspects of diabetic neuropathy. Special Topics in Endocrinology and Metabolism 3: 1–43, 1982

    PubMed  Google Scholar 

  • Consensus Statement. Report and recommendations of the San Antonio Conference on Diabetic Neuropathy. Diabetes 37: 1000–1004, 1988

    Google Scholar 

  • Culebras A, Alio J, Herrera J-L, Lopez-Fraile IP. Effect of an aldose reductase inhibitor on diabetic peripheral neuropathy. Archives of Neurology 38: 133–134, 1981

    Article  PubMed  CAS  Google Scholar 

  • Dyck PJ. Detection, characterisation and staging of polyneuropathy, assessed in diabetics. Muscle and Nerve 11: 21–32, 1988

    Article  PubMed  CAS  Google Scholar 

  • Dyck PJ, Bushek W, Spring EM, Karnes JL, Litchy WJ, et al. Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy. Diabetes Care 10: 432–440, 1987

    Article  PubMed  CAS  Google Scholar 

  • Dyck PJ, Karnes JL, O’Brien P, Okazaki H, Lais A, et al. The spatial pattern of fibre loss in diabetic neuropathy suggests ischaemia. Annals of Neurology 19: 440–449, 1986

    Article  PubMed  CAS  Google Scholar 

  • Dyck PJ, Sherman WS, Hallcher LM, Service FJ, O’Brien PC, et al. Human diabetic endoneurial sorbitol, fructose and myoinositol related to sural nerve morphometry. Annals of Neurology 8: 590–596, 1980

    Article  PubMed  CAS  Google Scholar 

  • Dyck PJ, Zimmerman BR, Vilen TH, Minnerath SR, Karnes JL, et al. Nerve glucose, fructose, sorbitol, myoinositol, and fiber degeneration and regeneration in diabetic neuropathy. New England Journal of Medicine 319: 542–548, 1988

    Article  PubMed  CAS  Google Scholar 

  • Fagius J, Brattberg A, Jameson S, Berne C. Limited benefit of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24 week controlled trial. Diabetologia 28: 323–329, 1985

    Article  PubMed  CAS  Google Scholar 

  • Fagius J, Jameson S. Effect of aldose reductase inhibitor treatment in diabetic polyneuropathy: a clinical and neurophysiological study. Journal of Neurology, Neurosurgery and Psychiatry 44: 991–1001, 1981

    Article  CAS  Google Scholar 

  • Florkowski CM, Rowe BR, Nightingale S, Barnett AH. A six month randomised placebo-controlled trial of the aldose reductase inhibitor ‘statil’ in chronic symptomatic peripheral neuropathy. In Ward JD (Ed.) Proceedings of the 1988 IDF Satellite Symposium on Diabetic Neuropathy, John Wiley & Sons Ltd, Chichester, in press, 1989

  • Flynn TG. The aldehyde reductase family of enzymes. Bulletin of the Canadian Biochemical Society 20: 38–44, 1983

    CAS  Google Scholar 

  • Gabbay KH. The sorbinil pathway and complications of diabetes. New England Journal of Medicine 194: 1085–1087, 1973

    Google Scholar 

  • Gabbay KH, Merola LO, Field RA. Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes. Science 151: 209–210, 1966

    Article  PubMed  CAS  Google Scholar 

  • Goto Y, Shigeta Y, Sakamoto N, Kito S, Matsuoka K. Clinical effect of aldose reductase inhibitor (ONO-2235) on diabetic neuropathy: multi-institutional studies. Abstracts of the International Symposium on the Polyol Pathway and its Role in Diabetic Complications, p. 15, Kashikojima, October 28–30, 1986

  • Greene DA, DeJesus PV, Winegrad AI. Effects of insulin and dietary myoinositol on impaired motor nerve conduction velocity in acute streptozotocin diabetes. Journal of Clinical Investigation 55: 1326–1336, 1975

    Article  PubMed  CAS  Google Scholar 

  • Greene DA, Lattimer SA. Action of sorbinil in diabetic peripheral nerve: relationship of polyol (sorbitol) pathway inhibition to a myoinositol mediated defect in sodium-potassium ATPase activity. Diabetes 33: 712–716, 1984

    Article  PubMed  CAS  Google Scholar 

  • Greene DA, Lattimer SA, Sima AAF. Are disturbances of Sorbitol, Phosphoinositide, and Na+-K+-ATPase regulation involved in the pathogenesis of diabetic neuropathy? Diabetes 37: 688–693, 1988

    Article  PubMed  CAS  Google Scholar 

  • Gregerson G, Bertelsen B, Harbo H, Larsen E, Anderson JR, et al. Oral supplementation of myoinositol: effects on peripheral nerve function in human diabetes and on the concentration in plasma, erythrocytes, urine, and muscle tissue in human diabetics and normals. Acta Neurologica Scandinavica 67: 164–172, 1983

    Article  Google Scholar 

  • Guy RJC, Gilbey SG, Sheehy M, Asselman P, Watkins PJ. Diabetic neuropathy in the upper limb and the effect of twelve months sorbinil treatment. Diabetologia 31: 214–220, 1988

    Article  PubMed  CAS  Google Scholar 

  • Hale PJ, Nattrass M, Silverman SH, Sennit C, Perkins CM, et al. Peripheral nerve concentrations of glucose, fructose, sorbitol and myoinositol in diabetic and non-diabetic patients. Diabetologia 30: 464–467, 1987

    Article  PubMed  CAS  Google Scholar 

  • Handelsman DJ, Turtle JR. Clinical trial of an aldose reductase inhibitor in diabetic neuropathy. Diabetes 30: 459–464, 1981

    Article  PubMed  CAS  Google Scholar 

  • Hotta N, Kakuta H, Koh N, Sakakibara F, Nakamura J, et al. A long-term experimental and clinical study of an aldose reductase inhibitor, ONO-2235 on diabetic neuropathy. In Ward JD (Ed.) Proceedings of the 1988 IDF Satellite Symposium on Diabetic Neuropathy, John Wiley & Sons Ltd, Chichester, in press, 1989

  • Jamal GA, Hansen S, Weir AI, Ballantync JP. An improved automated method for the measurement of thermal thresholds. 1. Normal subjects. Journal of Neurology, Neurosurgery and Psychiatry 48: 354–360, 1985

    Article  CAS  Google Scholar 

  • Jaspan J, Herold K, Maselli R, Bartkus C. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomie function. Lancet 2: 758–762, 1983

    Article  PubMed  CAS  Google Scholar 

  • Judzewitsch RG, Jaspan JB, Polonsky KS, Weinberg CR, Halter JB, et al. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. New England Journal of Medicine 308: 119–125, 1983

    Article  PubMed  CAS  Google Scholar 

  • Lewin IG, O’Brien IAD, Morgan MH, Corrall RJM. Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy. Diabetologia 26: 445–448,1984

    Article  PubMed  CAS  Google Scholar 

  • Llewelyn JG, Thomas PK, Gilbey SG, Watkins PJ, Muddle JR. Pattern of myelinated fibre loss in the sural nerve in neuropathy related to Type 1 (insulin-dependent) diabetes. Diabetologia 31: 162–167, 1988

    Article  PubMed  CAS  Google Scholar 

  • Low PA. Recent advances in the pathogenesis of diabetic neuropathy. Muscle and Nerve 10: 121–128, 1987

    Article  PubMed  CAS  Google Scholar 

  • Low PA, Schmelzer JD, Ward KK, Yao JK. Experimental chronic hypoxic neuropathy: relevance to diabetic neuropathy. American Journal of Physiology 250: E94–99, 1986

    PubMed  CAS  Google Scholar 

  • Malik RA, Newrick PG, Sharma AK, Tomlinson DR, Ward JD. Pathogenesis of human diabetic neuropathy. In Ward JD (Ed.) Proceedings of the 1988 IDF Satellite Symposium on Diabetic Neuropathy, John Wiley & Sons Ltd, Chichester, in press, 1989

  • Masson EA, Church SE, Woodcock AA, Hanley SP, Boulton AJM. Is resistance to ischaemic conduction failure induced by hypoxia? Diabetologia 31: 762–765, 1988

    Article  PubMed  CAS  Google Scholar 

  • Masson EA, Gem J, Hunt L, Boulton AJM. A novel approach to diagnosis and assessment of symptomatic diabetic neuropathy. Pain 38: 25–28, 1989

    Article  PubMed  CAS  Google Scholar 

  • Mayer JH, Tomlinson DR. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myoinositol or an aldose reductase inhibitor in streptozotocin-diabetic rats. Diabetologia 25: 433–438, 1983

    Article  PubMed  CAS  Google Scholar 

  • Mayhew JA, Grillon KRW, Hawthorne JN. Free and lipid inositol, sorbitol, and sugars in sciatic nerve obtained post-mortem from diabetic patients and control subjects. Diabetologia 24: 13–15, 1983

    Article  PubMed  CAS  Google Scholar 

  • Mulder DW, Lambert EH, Bastron JA, Sprague RG. The neuropathies associated with diabetes mellitus: a clinical and electromyographic study of 103 unselected diabetic patients. Neurology 11: 275–284, 1961

    PubMed  Google Scholar 

  • Nakuda H. Increased susceptibility to ischaemia in diabetic nerve. Abstract ORA-014-005. Diabetes Research and Clinical Practice 5 (Suppl. 1): S57, 1988

    Google Scholar 

  • Newrick PG, Wilson AJ, Jakubowski J, Boulton AJM, Ward JD. Sural nerve oxygen tension in diabetes. British Medical Journal 293: 1053–1054, 1986

    Article  PubMed  CAS  Google Scholar 

  • O’Hare JP, Morgan MH, Alden P, Chissel S, O’Brien IAD, et al. Aldose reductase inhibition in diabetic neuropathy: clinical and neurophysiological studies of one year’s treatment with sorbinol. Diabetic Medicine 5: 537–542, 1988

    Article  PubMed  Google Scholar 

  • Pavy FW. Address on diabetes, Washington International Congress. Medical News (Philadelphia) September 24: 357, 1887

    Google Scholar 

  • Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4,400 patients between 1947 and 1973. Diabetes Care 1: 168–188, 252–263, 1978

    Google Scholar 

  • Pitts NE, Gundersen K, Mehta DJ, Vreeland F, Shaw GL, et al. Clinical experience with sorbinil: an aldose reductase inhibitor. Metabolism 35 (Suppl. 1): 96–100, 1986

    Article  PubMed  CAS  Google Scholar 

  • Ryder S, Sarokhan B, Shand DG, Mullane JF. Human safety profile of tolrestat: an aldose reductase inhibitor. Drug Development Research 11: 131–143, 1987

    Article  Google Scholar 

  • Ryder S, the Tolrestat in Painful Neuropathy Study Group. Objective (nerve conduction) and subjective (painful symptom) improvement following administration of tolrestat, a new aldose reductase inhibitor. Abstract No. 436, Diabetologia 29: 588A, 1986

    Google Scholar 

  • Salway JG, Finnegan JA, Barnett D, Whitehead L, Karunanyaka A, et al. Effect of myoinositol on peripheral nerve function in diabetes. Lancet 2: 1282–1284, 1978

    Article  PubMed  CAS  Google Scholar 

  • Sima AAF, Bril V, Nathaniel V, McEwen TA, Brown MB, et al. Regeneration and repair of myelinated fibres in sural nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. New England Journal of Medicine 319: 548–555, 1988

    Article  PubMed  CAS  Google Scholar 

  • Sima AAF, Lattimer SA, Yagihashi S, Greene DA. Axo-glial dysjunction: a novel structural lesion that accounts for poorly reversible slowing of nerve conduction in the spontaneously diabetic bio-breeding rat. Journal of Clinical Investigation 77: 474–484, 1986

    Article  PubMed  CAS  Google Scholar 

  • Simard-Dequesne N, Greslin E, Dubuc J, Dvornik D. The effect of a new aldose reductase inhibitor (tolrestat) in galactosacmic and diabetic rats. Metabolism 33: 885–892, 1985

    Article  Google Scholar 

  • Solders G. Gunnarsson R. Persson A, Wilczek H, Tyden G, et al. Effects of combined pancreatic and renal transplantation on diabetic neuropathy: a two-year follow-up study. Lancet 2: 1232–1235. 1987

    Google Scholar 

  • Sredy J. Millen J. McCaleb ML, Tutwiler GF. Inhibition of polyol accumulation in lens, sciatic nerve, and RBC in vitro by the aldose reductase inhibitor, tolrestat. Federation Proceedings 45: 902. 1986

    Google Scholar 

  • Stewart MA, Sherman WR, Kurien MM, Moonsammy GI, Wisgerhof M. Polyol accumulation in nervous tissue of rats with experimental diabetes and galactosaemia. Journal of Neurochemistry 14: 1057–1066, 1967

    Article  PubMed  CAS  Google Scholar 

  • Terkildsen AB, Christensen NJ. Reversible nervous abnormalities in juvenile diabetics with recently diagnosed diabetes. Diabetologia 7: 113–117. 1971

    Article  PubMed  CAS  Google Scholar 

  • Thomas PK, Eliasson SG. Diabetic neuropathy. In Dyck PJ et al. (Eds) Peripheral neuropathy, pp. 956–981, Saunders, Philadelphia, 1975

    Google Scholar 

  • Timperley WR, Boulton AJM, Davies-Jones GAB, Jarratt JA, Ward JD. Small vessel disease in progressive diabetic neuropathy associated with good metabolic control. Journal of Clinical Pathology 38: 1030–1038, 1985

    Article  PubMed  CAS  Google Scholar 

  • Tomlinson DR, Moriarty RJ, Mayer JH. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil. Diabetes 33: 470–476, 1984

    Article  PubMed  CAS  Google Scholar 

  • Tuck RR, Schmelzer JD, Low PA. Endoneurial blood flow and oxygen tension in the sciatic nerves of rats with experimental diabetic neuropathy. Brain 107: 935–950, 1984

    Article  PubMed  Google Scholar 

  • Turtle JR. Aldose reductase in the pathophysiological aspects of diabetic neuropathy. Abstracts of the International Symposium on the Polyol Pathway and its Role in Diabetic Complications, p. 10; Kashikojima, October 28–30, 1986

  • Van Heyningen R. Formation of polyols in the lens of the rat with ‘sugar’ cataract. Nature 184: 194–195, 1959

    Article  Google Scholar 

  • Ward JD, Barnes CG, Fisher DJ, Jessop JD. Improvement in nerve conduction following treatment in newly diagnosed diabetics. Lancet 1: 428–431, 1971

    Article  PubMed  CAS  Google Scholar 

  • Williams G, Gills JS, Aber V, Mather HM. Variability in vibration perception threshold among sites: a potential source of error in biothesiometry. British Medical Journal 296: 233–235, 1988

    Article  PubMed  CAS  Google Scholar 

  • Winegrad AI, Simmons DA, Martin DB. Pathogenesis of diabetic neuropathy. Correspondence. New England Journal of Medicine 320: 58–59, 1989

    Google Scholar 

  • Yasuda H, Dyck PJ. Abnormalities of endoneurial microvessels and sural nerve pathology in diabetic neuropathy. Neurology 37: 20–28, 1987

    Article  PubMed  CAS  Google Scholar 

  • Young RJ, Ewing DJ, Clarke BP. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes 32: 938–942, 1983

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester, M13 9WL, England

    E. A. Masson &  A. J. M. Boulton (Senior Lecturer in Medicine and Honorary Consultant Physician)

Authors
  1. E. A. Masson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. J. M. Boulton
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Masson, E.A., Boulton, A.J.M. Aldose Reductase Inhibitors in the Treatment of Diabetic Neuropathy. Drugs 39, 190–202 (1990). https://doi.org/10.2165/00003495-199039020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199039020-00003

Keywords

Search

Navigation